St. John Fisher University

Fisher Digital Publications
Pharmacy Faculty/Staff Publications

Wegmans School of Pharmacy

12-11-2016

Kaempferol-Phospholipid Complex: Formulation, and Evaluation
of Improved Solubility, In Vivo Bioavailability, and Antioxidant
Potential of Kaempferol
Darshan R. Telange
Nagpur University

Arun T. Patil
Nagpur University

Anil M. Pethe
SVKM's NMIMS University

Amol A. Tatode
Nagpur University

Sridhar Anand

Follow
and University
additional, works
at: https://fisherpub.sjf.edu/pharmacy_facpub
St. Johnthis
Fisher
sanand@sjf.edu
Part of the Pharmacy and Pharmaceutical Sciences Commons

How
hasforopen
to Fisher Digital Publications
See next page
additionalaccess
authors
benefited you?
Publication Information
Telange, Darshan R.; Patil, Arun T.; Pethe, Anil M.; Tatode, Amol A.; Anand, Sridhar; and Dave, Vivek S.
(2016). "Kaempferol-Phospholipid Complex: Formulation, and Evaluation of Improved Solubility, In Vivo
Bioavailability, and Antioxidant Potential of Kaempferol." Journal of Excipients and Food Chemicals 7.4,
89-116.
Please note that the Publication Information provides general citation information and may not be
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit
http://libguides.sjfc.edu/citations.

This document is posted at https://fisherpub.sjf.edu/pharmacy_facpub/128 and is brought to you for free and open
access by Fisher Digital Publications at . For more information, please contact fisherpub@sjf.edu.

Kaempferol-Phospholipid Complex: Formulation, and Evaluation of Improved
Solubility, In Vivo Bioavailability, and Antioxidant Potential of Kaempferol
Abstract
The current work describes the formulation and evaluation of a phospholipid complex of kaempferol
toenhance the latter’s aqueous solubility, in vitro dissolution rate, in vivo antioxidant and
hepatoprotectiveactivities, and oral bioavailability. The kaempferol-phospholipid complex was
synthesized using a freeze-drying method with the formulation being optimized using a full factorial
design (32) approach. The resultsinclude the validation of the mathematical model in order to ascertain
the role of specific formulation andprocess variables that contribute favorably to the formulation’s
development. The final product wascharacterized and confirmed by Differential Scanning Calorimetry
(DSC), Fourier Transform InfraredSpectroscopy (FTIR), Proton Nuclear Magnetic Resonance Spectroscopy
(1H-NMR), and Powder X-rayDiffraction (PXRD) analysis. The aqueous solubility and the in vitro
dissolution rate were enhanced comparedto that of pure kaempferol. The in vivo antioxidant properties of
the kaempferol-phospholipid complex wereevaluated by measuring its impact on carbon tetrachloride
(CCl4)-intoxicated rats. The optimizedphospholipid complex improved the liver function test parameters
to a significant level by restoration of allelevated liver marker enzymes in CCl4-intoxicated rats. The
complex also enhanced the in vivo antioxidantpotential by increasing levels of GSH (reduced glutathione),
SOD (superoxide dismutase), catalase anddecreasing lipid peroxidation, compared to that of pure
kaempferol. The final optimized phospholipidcomplex also demonstrated a significant improvement in
oral bioavailability demonstrated by improvementsto key pharmacokinetic parameters, compared to that
of pure kaempferol.
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ABSTRACT
The current work describes the formulation and evaluation of a phospholipid complex of kaempferol to
enhance the latter’s aqueous solubility, in vitro dissolution rate, in vivo antioxidant and hepatoprotective
activities, and oral bioavailability. The kaempferol-phospholipid complex was synthesized using a freezedrying method with the formulation being optimized using a full factorial design (32) approach. The results
include the validation of the mathematical model in order to ascertain the role of specific formulation and
process variables that contribute favorably to the formulation’s development. The final product was
characterized and confirmed by Differential Scanning Calorimetry (DSC), Fourier Transform Infrared
Spectroscopy (FTIR), Proton Nuclear Magnetic Resonance Spectroscopy (1H-NMR), and Powder X-ray
Diffraction (PXRD) analysis. The aqueous solubility and the in vitro dissolution rate were enhanced compared
to that of pure kaempferol. The in vivo antioxidant properties of the kaempferol-phospholipid complex were
evaluated by measuring its impact on carbon tetrachloride (CCl4)-intoxicated rats. The optimized
phospholipid complex improved the liver function test parameters to a significant level by restoration of all
elevated liver marker enzymes in CCl4-intoxicated rats. The complex also enhanced the in vivo antioxidant
potential by increasing levels of GSH (reduced glutathione), SOD (superoxide dismutase), catalase and
decreasing lipid peroxidation, compared to that of pure kaempferol. The final optimized phospholipid
complex also demonstrated a significant improvement in oral bioavailability demonstrated by improvements
to key pharmacokinetic parameters, compared to that of pure kaempferol.
KEY WORDS: Phospholipids, solubility, dissolution, bioavailability, antioxidant

INTRODUCTION

Kaempferol is a bioflavonoid that is commonly
present in many fruits and vegetables. It is
known to be a potential antioxidant based on

its use in plant-derived foods and traditional
medicines (1). Following oral administration,
kaempferol has been reported to produce a
range of pharmacological activities including
antioxidant, anti-cancer, anti-inflammatory,
hepato-protective, neuroprotective, and
osteogenic activities(2-7). This makes
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kaempferol an attractive formulation target and
subject of this investigation.
Despite these positive and favorable health
benefits of kaempferol, its low bioavailability
and rapid metabolism impair its oral delivery.
Following oral administration, kaempferol
undergoes extensive first-pass hepatic
metabolism through phase II reactions viz.
methylation, sulfation, or glucuronidation (8).
Keeping in mind the potential health benefits
listed above, we have sought to develop the
appropriate formulation technique to enhance
kaempferol’s poor absorption and oral
bioavailability.
Enhancement of bioavailability is a well-studied
phenomenon. Numerous emerging formulation
techniques and strategies for the improvement
of oral bioavailability have been described in
literature. These include liposomes, solid lipid
nanoparticles, and self-nanoemulsifying drug
delivery systems (SNEDDS). Seguin et. al.
formulated fisetin-based liposomes to improve
its bioavailability and anti-tumor efficacy; the
results demonstrated that the liposomal
formulation enhanced the relative bioavailability
up to 47-fold, as compared to free fisetin (9).
Ruan et. al. developed a self-nanoemulsifying
drug delivery system (SNEDDS) for the
delivery of matrine (11). Their results showed
that the relative bioavailability in rat serum
increased nearly 10-fold compared to free
mangiferin. According to these formulation
strategies, the poor absorption and oral
bioavailability of these phytocompounds were
found to progress in excellent manner when
complexed with phospholipids. The
phospholipids act as a biocompatible carrier
system for most of the phytocompounds for
improving their poor aqueous solubility, in vitro
dissolution rate, poor absorption, oral
bioavailability, and pharmacological activity.
Previously published reports show that the
kaempferol exhibits good hepatoprotective and
antioxidant effects.
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Zhang et. al. reported that kaempferolphospholipids complex in an equimolar ratio
(1:1), enhanced the aqueous solubility, in vitro
dissolution rate, and pharmacokinetic and oral
bioavailability in rats (12). However, this study
was limited in several aspects including the lack
of formulation optimization, the dissolution
being carried out for only 2 hours, the lack of
reported improvements in bioavailability, and
the lack of in vivo antioxidant studies. The
current work presents a systematic and a
comprehensive study on the formulation of
kaempferol-phospholipid complex, by
including a more elaborate physical and
functional characterization. In this study,
kaempferol-phospholipids complex was
prepared by freeze-drying technique to produce
a stable complex in a powder form with
spherical particle morphology. A full factorial
design (32) strategy was employed to understand
the influence of various formulation/process
variables and to optimize the formulation. A
detailed physical characterization of the designoptimized complex was carried out by particle
size analysis, zeta potential measurements,
thermal analysis, infrared analysis, powder x-ray
diffraction analysis, proton nuclear magnetic
resonance spectroscopy, and solubility analysis.
The prepared complex was further functionally
characterized by in vitro dissolution studies, in
vivo antioxidant and hepatoprotective activity,
and pharmacokinetic analysis.
MATERIALS AND METHODS
Materials

Kaempferol (~ 99% pure) was obtained from
Imam International Group (Pharmaceutical)
Co., Ltd., Tianjin, China. Phospholipon® 90H
(>90% pure) was received as a gift from Lipoid
GmbH, Ludwigshafen, Germany. Carbon
tetrachloride, chloroform, 1,4-dioxane, ethylene
diamine tetra acetic acid (EDTA), 5,5’-dithiobis
(2-nitrobenzoic acid) (DTNB), sodium
chloride, and sodium lauryl sulfate (SLS) were
obtained from Loba Chemicals Pvt. Ltd.,
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Mumbai, India. n-hexane, n-octanol, mphosphoric acid, thiobarbituric acid (TBA), and
trichloroacetic acid (TCA) were obtained from
Sigma Chemicals, Sigma-Aldrich Corporation,
St. Louis, MO. All other chemicals used in this
investigational work were of analytical grade.

The non-complexed/free kaempferol residue
was air-dried, dissolved in methanol, and after
appropriate dilutions, analyzed on a UV-visible
spectrophotometer (Model: V-630, JASCO
International Co. Ltd., Tokyo, Japan) at 365 nm
for kaempferol.

Formulation of the kaempferol-phospholipid
complex (KPLC)

Design of Experiments

The kaempferol-phospholipid complex (KPLC)
was prepared according to the method reported
earlier (13). Briefly, kaempferol (Mol. Wt.
286.24) and Phospholipon® 90H (Mol. Wt. 790)
were weighed accurately and placed in a 100 ml
round bottom flask. Based on the exploratory
experiments carried out earlier, kaempferol and
Phospholipon® 90H were used in molar ratios
of 1:1, 1:2, and 1:3. Both ingredients were
dissolved in 1, 4-dioxane (20 ml) and refluxed.
The reflux reactions were carried out at 40°C,
50°C, and 60°C using a water bath for a period
of two hours. After two hours, the reaction
mixture was freeze-dried using a lyophilizer
(Model: MSW-137, Macro Scientific Works Pvt.
Ltd., New Delhi, India). The resulting
lyophilized KPLC was placed in amber colored
glass vials, flushed with nitrogen, and stored at
room temperature until further use.

Preliminary studies carried out in-house and
reports published elsewhere identified the main
factors and their ranges in influencing the
formation of KPLC (15). These factors were
drug: phospholipid ratio (X1, w: w) and the
reaction temperature (X2, ºC), and were chosen
at three levels (low, middle, and high) for each
factor resulting in a full-factorial design (32)
composed of nine independent experimental
trials. The dependent variable for the study was
% yield, i.e. the fraction of kaempferol
entrapped by weight in the prepared complex.
All nine combinations of selected independent
variables were used to carry out the
experiments. The results of these experiments
were analyzed using a mathematical model
described by the Equation 1 below, exhibiting
coefficient effects, interactions, and polynomial
terms.
Y = b0 + b1X1 + b2X2 + b3X12 + b4X22 + b5X1X2

Estimation of kaempferol in the prepared
KPLC (% yield)

The extent of kaempferol incorporation in the
prepared complex was estimated using a
spectrophotometric method described
previously (14). Briefly, accurately weighed
KPLC (~10 mg kaempferol) was dispersed in
5 ml chloroform. The formed complex and
pure Phospholipon® 90H were dissolved in
chloroform. Free/non-complexed kaempferol
remains insoluble in chloroform and
precipitates out. The dispersion was then
filtered using a filter paper (Whatman®
quantitative filter paper, ash-less, Grade 41,
Sigma-Aldrich Corporation, St. Louis, MO).

This Journal is © IPEC-Americas Inc

Eq. 1

In this equation, Y is the % yield, b is the
coefficient of the independent variable X. The
independent effects of both factors at different
levels are represented as the main effects, X1
and X2. The combined effect of the
independent variables is shown by the
interaction term X1X2. The non-linearity of the
response is described by the polynomial terms
X12 and X22. Table 1 shows the experimental
design and the actual values of the independent
variables. Table 2 shows the experimentally
obtained values of the dependent variable, i.e.
% yield for each experiment.
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Table 1 Coded levels and “real” values for each factor
LEVELS

VARIABLES
-1

0

+1

Real values

Independent
Kaempferol : Phospholipids ratio (X1, w:w)

1:1

1:2

1:3

Reaction temperature (X2, ºC)

40

50

60

Dependent

The prepared KPLC was also evaluated for
physical stability by analyzing its zeta potential
using Nano particle analyzer (Model:
NanoPlusTM-2, Particulate systems, Norcross,
GA, USA) equipped with dynamic light
scattering. The zeta potential of the sample was
measured in the sensitivity range of +200 to 200 mV.

Extent of complexation or Yield (Y, % w/w)

Differential Scanning Calometry (DSC)
Table 2 Full factorial design (32) experimental trial
batches, with obtained yield values (%, w/w)
EXPERIMENTAL
TRIALS

X1

X2

EXTENT OF
COMPLEXATION,
OR YIELD* (%, w/w)

1

0

+1

88.49 ± 1.48
89.27 ± 0.82

2

0

0

3

-1

-1

92.80 ± 0.75

4

+1

+1

84.15 ± 0.67

5

+1

-1

81.68 ± 1.61

6

-1

0

95.25 ± 1.17

7

+1

0

84.70 ± 1.53

8

0

-1

86.26 ± 0.91

9

-1

+1

93.49 ± 1.32

*Values are represent mean ± Std. Dev. (n = 3)

Physicochemical characterization

Fourier
(FTIR)

Particle size analysis and zeta potential

The particle size distribution of the prepared
KPLC was analyzed using Photon CrossCorrelation Spectroscopy (PCCS) with dynamic
light scattering setup (16). In a sample vial, ~5
mg of KPLC powder was dispersed in 10 ml
deionized water. The analyzer (Model:
NANOPHOX, Sympatec GmbH, ClausthalZellerfeld, Germany) with a sensitivity range of
1 nm to 10 μm was used to analyze this
dispersion. The software associated with the
instrument was used to optimize the count rate
by appropriate positioning of the dispersion
sample vial. The measurements were carried out
at 25ºC.
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The thermal behavior of the samples, viz., pure
kaempferol, pure Phospholipon® 90H, the
physical mixture (PM) of kaempferol and
Phospholipon® 90H, and the prepared KPLC
was analyzed by differential scanning
calorimetry (Model: DSC-1 821e, MettlerToledo AG, Analytical, Schwerzenbach,
Switzerland). The instrument was calibrated
with a high-purity indium standard, and
continuously purged with dry nitrogen (50
ml/min) to provide a non-oxidizing
environment. Each sample (2.0 ± 0.2 mg) was
subjected to a single heating cycle at a heating
rate of 10°C min-1, with the temperature
ranging from 40°C to 400°C. The instrument
software (Universal Analysis 2000) was used to
analyze the thermal events associated with the
samples.
Transform

Infrared

Spectroscopy

A Fourier-transform infrared spectrometer
(Model: FTIR-8300, Shimadzu, Kyoto, Japan)
was used to study the physicochemical
characteristics of pure kaempferol, pure
Phospholipon® 90H, the physical mixture of
kaempferol and Phospholipon® 90H (PM), and
the prepared KPLC. In brief, previously dried
samples (~2 mg) were weighed individually and
transferred into agate mortar and pestle. The
individually weighed samples were mixed
uniformly with potassium bromide (KBr, FTIR grade, ~200 mg) to form a homogenous
mixture. This mixture was compressed at a
pressure of 10/Nm2 Ton to obtain thin,
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transparent discs on a mini hand press (Model:
MHP - 1, P/N - 200-66747-91, Shimadzu,
Kyoto, Japan). The sample discs were scanned
to obtain infrared spectra in the wavelength
range of 4000 to 400 cm-1 at a resolution of 4
cm-1. The obtained spectra were processed and
analyzed using instrument software (IRsolution
FTIR control software, version 1.10).
Proton Nuclear Magnetic Resonance
(1H-NMR)
1

H-NMR spectroscopy was used to compare
the carbon-hydrogen framework of individual
components as well as the prepared complex.
The individual samples of pure kaempferol,
pure Phospholipon® 90H, PM, and KPLC were
analyzed to obtain 1H-NMR spectra on a 400
MHz FT-NMR spectrometer (Bruker Advance
II, Bruker, Rheinstatten, Germany).

Solubility analysis

Pure kaempferol, PM, and KPLC were
analyzed for their aqueous and n-octanol
solubilities using a method previously reported
by Saoji, et. al. (16). Briefly, an excess amount of
each sample was transferred to a sealed glass
vial containing 5 ml of water/or n-octanol. This
dispersion was allowed to agitate on a water
bath shaker (Model: RSB-12, Remi house,
Mumbai, India) for 24 hours. The agitated
dispersion was centrifuged using a
microcentrifuge (Model: RM-12C, Angle Rotor
Head, Remi House, Goregaon (E), Mumbai,
India) for 25 minutes at 1500 RPM and filtered
through a membrane filter (0.45 µ). An aliquot
of this filtrate was suitably diluted with water or
n-octanol, and assayed using UV-visible
spectrophotometer (Model: V-630, JASCO
International Co. Ltd., Tokyo, Japan) at 365 nm
for kaempferol. All experiments were carried
out at room temperature (25°C).

Powder X-ray Diffractometry (PXRD)
Functional characterization

The crystal state of pure kaempferol,
Phospholipon® 90H, PM, and KPLC was
analyzed using a powder x-ray diffractometer
(Model: D8 ADVANCE, Bruker AXS, Inc.,
Madison, WI, USA) accompanied by a BraggBrentano geometry (θ/2θ) optical setup. In
brief, an accurately weighed (~1 g) sample was
mounted into the sample holder. The
diffractometer was equipped with a CuKβ
anode x-ray monochromatic radiation
generating tube source. The sample was
irradiated at a wavelength of λ = 1.5406 Å with
photon energy in the range of 100 eV to 100
keV. The functional voltage and current were
maintained at 30 mV and 10 mA, respectively.
A one-dimensional detector (LYNXEYETM)
was used to process and convert the individual
signal to a spectrum. The spectra of the
scanned samples were obtained on the 2θ scale
with a diffraction angle range of 3° 2θ to 60° 2θ
at a count rate of five seconds.

This Journal is © IPEC-Americas Inc

In vitro dissolution studies

The dissolution behavior of pure kaempferol
and the prepared KPLC was analyzed using a
dialysis method previously reported by Maiti, et.
al. (17). Briefly, the dissolution study was
carried out using a dialysis bag prepared from a
membrane (LA393, Dialysis Membrane-70,
HiMedia Laboratories, Mumbai, India) of fixed
dimensions (17.5 mm x 28.46 mm) and a
capacity of 2.41 ml/min. The membrane was
reported to retain molecules over 12000 KDa.
The membrane, after pre-treatment according
to the manufacturer’s instructions, was tied to
form the dialysis bag. The samples of pure
kaempferol suspension (2 ml, 2 mg/ml of
kaempferol) or the prepared KPLC (~4 mg
kaempferol) were placed in the bag. The bag
was suspended vertically into a beaker
containing phosphate-buffered saline (PBS, 200
ml, pH 7.4) and Tween® 20 (1 % v/v) as a
surfactant. The entire assembly was stirred at 50
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rpm using a magnetic stirrer, and maintained at
a temperature of 37.0 ± 2.0°C. 5 ml aliquots of
the sample were withdrawn at specific time
intervals, and analyzed on a UV-visible
spectrophotometer (Model: V-630, JASCO
International Co. Ltd., Tokyo, Japan) at 365 nm
for kaempferol.
In vivo antioxidant activity

The in vivo antioxidant activity of pure
kaempferol and the optimized KPLC was
comparatively evaluated in a rodent model. This
well-established method for the investigation
uses carbon tetrachloride (CCl4) – induced
oxidative toxicity in rats, and has been reported
earlier in the literature (17, 18). The
Institutional Animal Ethics Committee (IAEC)
of the Univ er s i ty Department of
Pharmaceutical Sciences (UDPS), R. T. M.
Nagpur University, Nagpur, India approved the
experimental protocol for the study
(UDPS/IAEC/2013–14/05, dated February
14, 2014). All the investigation procedures
followed the ethical guidelines provided by the
Committee for the Purpose of Control and
Supervision of Experiments on Animals
(CPCSEA).
Animals

The animals used for the evaluation of in vivo
antioxidant activity of pure kaempferol and the
optimized KPLC were male and female albino
rats (Wistar strain, bred in-house, 150-200
grams). These animals were housed in colony
cages at controlled temperature (25 ± 5°C) and
humidity (50 ± 5% RH) conditions, with a 12
hour light/dark cycle. The food (pellet chow,
Brooke Bond, Lipton, India) and water were
provided ad libitum.
Dosing and sample collection

The experimental animals were segregated into
four groups of six animals each. Group I
received the vehicle, i.e. Tween® 20 (1% v/v,
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p.o.) in distilled water for seven days, and
served as blank (negative control). Group II
received the single dose of a mixture of CCl4
and olive oil (1:1, 5ml/kg, i.p.) on the seventh
day, and served as positive control. Group III
received a pure kaempferol suspension
containing 1% v/v of Tween® 20 (25 mg/kg,
p.o.) for seven days. Group IV received the
KPLC suspension containing 1% v/v of
Tween® 20 (~25 mg/kg, p.o.) for seven days.
Additionally, on the seventh day, both the
groups III and IV also received a single dose of
mixture of CCl4 and olive oil (1:1, 5ml/kg, i.p.).
On the eighth day, following 24 hours of CCl4
intoxication, all groups of animals were
euthanized by cervical decapitation under light
ether anesthesia. The blood samples from all
the animals were collected into a heparinized
tube and centrifuged using a microcentrifuge
(Model: RM-12C, Angle Rotor Head, Remi
House, Goregaon (E), Mumbai, India). The
supernatant plasma samples were employed in
the estimation of liver marker enzymes (liver
function test). Later, the livers of the animals
were removed, and individually washed with ice
cold saline solution. These livers were then
used to prepare liver homogenate (10% w/v)
by homogenizing in 0.1 M phosphate buffer
saline (PBS, pH 7.4). The prepared homogenate
was then centrifuged using a microcentrifuge
(Model: RM-12C, Angle Rotor Head, Remi
House, Goregaon (E), Mumbai, India) to
obtain a clear supernatant for the estimation of
antioxidant marker enzymes.
Liver marker enzyme estimation (liver function
test)

Quantitative determination of serum glutamic
oxaloacetic transaminase (SGOT), serum
glutamic pyruvic transaminase (SGPT), serum
alkaline phosphatase (SALP), and total bilirubin
was carried out to compare the influence of
pure kaempferol and the prepared KPLC on
liver function in rats. A well-established
method, previously reported by Reitman and
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Frankel, was used to estimate SGOT and SGPT
levels (19). In brief, the substrates (0.5 ml) for
SGOT [α-L-alanine (200 mM), or SGPT [Laspartate (200 mM) with 2 mM α-ketoglutarate]
were incubated for 5 minutes at 37°C. Rat
plasma (0.1 ml) was added to the substrate and
phosphate buffer (pH 7.4, 0.1 M) was used to
make up the final volume to 1 ml. The mixture
was then incubated for 30 minutes (for SGPT)
or 60 minutes (for SGOT) at 37°C. 2, 4 –
dinitrophenyl hydrazine (0.5 ml, 1 mM) was
added as an indicator and the mixture incubated
further for 30 minutes. After 30 minutes,
sodium hydroxide (5 ml, 0.4 N) was added to
the reaction mixture, and the solution was
spectroscopically analyzed at 505 nm.
The plasma SALP levels were estimated using
‘Grifols-Lucas method’ reported earlier by Kind et.
al. (20). Briefly, phenyl phosphate substrate (1
ml, 0.5 N) was added to bicarbonate buffer (1
ml, pH 10) and incubated for three minutes at
37°C. Rat plasma (0.1 ml) was added to this
solution and the mixture was further incubated
for 15 minutes. Following incubation, sodium
hydroxide (0.8 ml, 0.5 N), sodium bicarbonate
(1.2 ml, 0.5 N), amino-antipyrine (1 ml, 0.6%),
and potassium ferricyanide (1 ml, 0.24%) were
added to the reaction mixture and thoroughly
mixed on a vortex mixer. The solution was then
analyzed spectroscopically at 520 nm.
The bilirubin content in rat plasma was
estimated using the procedure described by
Malloy et. al. (21). Briefly, rat plasma (0.25 ml)
and sodium nitrate (0.1 ml, 144 mmol/L) were
added to an aqueous solution of sulfanilic acid
(5 ml, 4 mmol/mL) and incubated for 10
minutes at 37°C. The absorbance of this
solution was measured at 670 nm.
Estimation of antioxidant marker enzymes

The quantitative determination of the enzymes
viz., glutathione (GSH), superoxide dismutase
(SOD), lipid peroxidase (LPO), and catalase
(CAT) in rat liver homogenate was carried out

This Journal is © IPEC-Americas Inc

to estimate the in vivo antioxidant activity of
pure kaempferol as well as the prepared KPLC.
A method established earlier by Ellman et. al.
was used to quantitatively estimate the GSH
levels (22). In brief, liver supernatant (0.2 ml),
distilled water (1.8 ml), and a precipitating
mixture, i.e. m-phosphoric acid (1.67 g), EDTA
(0.2 g), and NaCl (30 g) in 100 ml distilled water
were added to a test tube, vortexed, and
centrifuged using a microcentrifuge (Model:
RM-12C, Angle Rotor Head, Remi House,
Goregaon (E), Mumbai, India). To the
separated supernatant (1 ml), phosphate buffer
(1.5 ml, 0.1 M), and 5, 5’-dithiobis-(2nitrobenzoic acid) (DTNB, Ellman’s reagent,
0.5 ml) were added and mixed well. The
resulting mixture was analyzed at 412 nm on a
UV-visible spectrophotometer (Model: V-630,
JASCO International Co. Ltd., Tokyo, Japan).
The results were expressed as µg/mg of
protein.
The SOD was quantified using a method
reported by Marklund et. al. (23). Briefly, liver
supernatant (20 µl), Tris-HCl buffer (2 ml, 75
mM, pH 8.2), EDTA (0.6 ml, 6 mM), and
pyrogallol solution (0.5 ml, 30 mM, freshly
prepared) were added to a test tube and mixed
well. This reaction mixture was
spectrophotometrically analyzed at 420 nm at
an interval 30 sec for 3 minutes to record any
changes in the absorbance over time. A 50%
inhibition in the rate of auto-oxidation of
pyrogallol was considered to be equivalent to
one unit of enzyme activity, and expressed as
units/mg of protein.
LPO was quantitatively estimated using a
method previously reported by Stocks et. al.
(24). Briefly, liver supernatant (0.5 ml), sodium
lauryl sulfate (0.8%, 0.2 ml), trichloroacetic acid
(20%, 1 ml), and thiobarbituric acid (0.8%, 1.5
ml) were added to a test tube and heated for 1
hour at 100°C. The reaction mixture was
cooled to room temperature (25°C). After
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cooling, distilled water (1 ml) was added to this
mixture, and the mixture centrifuged using a
microcentrifuge (Model: RM-12C, Angle Rotor
Head, Remi House, Goregaon (E), Mumbai,
India) to separate the aqueous and the organic
layer. The organic layer was collected and
analyzed spectroscopically (Model: V-630,
JASCO International Co. Ltd., Tokyo, Japan) at
532 nm. The lipid peroxidation was calculated
on the basis of the molar extinction coefficient
of malondialdehyde (MDA) (1.56 x 105 M-1 cm1
), and represented as MDA (nM/g) in
hemoglobin.
A method reported previously by Beer et. al.
was used for the quantitative estimation of
CAT (25). Briefly, a reaction mixture was
prepared by mixing liver supernatant (0.1 ml),
phosphate buffer (1.9 ml, 50 mM, pH 7.4), and
freshly prepared hydrogen peroxide (1.0 ml).
The reaction mixture was spectroscopically
(Model: V-630, JASCO International Co. Ltd.,
Tokyo, Japan) at 240 nm. The extent of
hydrogen peroxide decomposition was
correlated to the amount of CAT.
Histopathological studies

On the completion of oral dosing of all the
samples, i.e. on the eighth day, all animals were
euthanized by cervical decapitation technique.
The livers were isolated, washed (in ice cold
saline solution), and preserved in neutral
buffered formalin (10% v/v) until further
processing. The livers were sectioned to the
desired size and stained using the hematoxylineosin reagent. The stained images were
examined using an optical microscope (Model:
DM2500, Leica Microsystems Inc., Buffalo
Grove, IL), and the images were captured at a
magnification of 400× with a digital camera
attached.

This Journal is © IPEC-Americas Inc

Oral bioavailability studies
Extraction of kaempferol from plasma and sample
preparation

The oral bioavailability after administration of
pure kaempferol, or the prepared KPLC was
investigated by extracting kaempferol from rat
plasma. The extraction procedure was adopted
from a previously reported method by Chen et.
al. (26). Briefly, two groups of six animals each
were fasted overnight with access to water ad
libitum. The first group received a single dose of
kaempferol (100 mg/kg, p.o.) and the second
group received a single dose of KPLC (~100
mg/kg, p.o. kaempferol). At predetermined
time intervals, the animals were anesthetized
and blood samples were obtained from the
retro-orbital plexus. These samples were
collected into Eppendorf ® Safe-Lock
microcentrifuge tubes (1.5 ml) and centrifuged
using a microcentrifuge (Model: RM-12C,
Angle Rotor Head, Remi House, Goregaon (E),
Mumbai, India) at 3000 rpm for 10 minutes.
The separated plasma was collected and stored
at -20°C until further use.
Kaempferol was extracted from the collected
plasma samples using a liquid-liquid extraction
technique. Briefly, a reaction mixture was
prepared by adding hydrochloric acid (25%,
200 μl) to the plasma sample (200 μl) in a test
tube followed by vortexing the mixture for 3
minutes. The sample was allowed to hydrolyze
for 60 minutes on a water bath at 80°C. After
allowing to cool to room temperature, ethyl
acetate (1 ml) was added, and the mixture
vortexed for additional 3 minutes. The mixture
was then centrifuged using a microcentrifuge
(Model: RM-12C, Angle Rotor Head, Remi
House, Goregaon (E), Mumbai, India) at 3000
RPM for 3 minutes to separate the aqueous and
the organic layer (I). The aqueous layer was
separated and further spiked with ethyl acetate
(1 ml), vortexed, and centrifuged at 3000 rpm
for 10 minutes to separate the aqueous and the
organic layers (II). The organic layers (I and II)
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were mixed together, transferred to a centrifuge
tube, and dried under a stream of nitrogen. The
dried residue was reconstituted in methanol
(100 µl) and centrifuged at 15000 RPM for 10
minutes. An aliquot (20 µl) from this solution
was analyzed using HPLC (Model: Thermo
ScientificTM, PDA, USA).

of the final measured sample (AUC06t), area
under the plasma concentration-time curve
from zero to infinity (AUC064), clearance
(Cl/F) and volume of distribution (Vz/F), and
the relative bioavailability (F).

High Performance Liquid Chomatograpy (HPLC)
analysis

The solubility and other in vitro study results are
reported as mean ± standard deviation. The
results from the liver function test, in vivo
antioxidant activity, and the pharmacokinetic
analysis are reported as mean ± standard error
of mean. The statistically significant differences
between the sample groups, if any, were
analyzed by one-way Analysis of Variance
(ANOVA) followed by Dunnett’s or Student’s
t-test. The p values of 0.05 or lower were
assumed as statistically significant.

The quantitative determination of kaempferol
in plasma samples was carried out using the
HPLC-based analysis described by Chen et. al.
(26). An automated HPLC system (Thermo
Scientific™ UltiMate™ 3000, Thermo Scientific,
San Jose, CA, USA) along with a Photo Diode
Array (PDA) detector (Thermo Scientific, San
Jose, CA, USA) was used to analyze the
samples. Hypersil GOLD™ C18 Selectivity LC
Column (100mm × 4.6mm), with a particle size
of 5 μm, was used as a stationary phase. The
mobile phase was composed of a mixture of
acetonitrile and phosphoric acid (0.4%), and
used for gradient elution. The flow rate of the
mobile phase was controlled at 1.0 ml/min to
ensure an effective resolution. The column
temperature was maintained at 30°C, and the
analyte detection wavelength was set at 360 nm.
Quercetin was used as an internal standard. The
mobile phase composition was optimized to
obtain the best possible resolution of
kaempferol peaks in the chromatogram. The
obtained peaks were analyzed, integrated, and
interpreted using the accompanying software.
Pharmacocinetic studies

The concentration-time curve provided the
main pharmacokinetic parameters, i.e.
maximum plasma concentration (Cmax) and the
time to reach maximum concentration (Tmax). A
popular statistical software (WinNonlin®,
Version 4.1, Certara USA Inc., Princeton, NJ,
USA) was used to calculate other parameters
such as half-life (t½), area under the plasma
concentration-time curve from zero to the time

This Journal is © IPEC-Americas Inc

Statistical analysis

RESULTS AND DISCUSSION
Formulation of
complex (KPLC)

kaempferol-phosphoolipids

The freeze-drying method was used to prepare
a stable complex of kaempferol with
phospholipids in the current study. Flavonoids
are known to be lipophilic molecules that
demonstrate fair solubility in organic solvents
(27). Bhattacharyya et. al. reported the use of
dichloromethane (DCM) as a solvent of choice
in the preparation of flavonoid-phospholipid
complexes (28). Other studies have also
reported the use of dichloromethane and/or
tetrahydrofuran (THF) as a solvent in the
preparation of similar complexes (14, 17, 18,
29). The preliminary solubility studies showed
that kaempferol was poorly soluble in the above
solvents, leading to the precipitation of
kaempferol in DCM and THF. Other organic
solvents were explored with respect to
kaempferol solubility and the preparation of
complex. It was found that the binary solvent
combination of 1, 4-dioxane (an aprotic solvent
with low dielectric constant) with methanol (a
similar aprotic solvent) in a ratio of 7:3 was an
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optimal system for the preparation of KPLC.

Validation of optimized model

Full factorial design

The design-generated optimized variables were
used to prepare an independent batch of KPLC
formulation with a goal to validate the
developed model. The predicted (theoretical)
yield from the developed model was compared
with the actual yield achieved from the
prepared formulation. This comparison
revealed that the actual yield (95.1%) was
slightly lower, albeit comparable to the modelpredicted yield (96.2%). The bias (-1.15%)
calculated using Equation 2 below, was also
found to be lower than 3%. These results
support the validity and robustness of the
developed model (30).

Table 2 shows the results obtained from the
experimental trials carried out using a 32 full
factorial design for the extent of KPLC
formation. Both the variables studied, i.e.
kaempferol:phospholipid ratio (X1, w:w) and
the reaction temperature (X2, °C), appeared to
influence the extent of complexation. The yield
(% kaempferol incorporated) values studied
ranged between 82 and 95% for the variables
studied. A quadratic model relating the yield to
the investigated variables was constructed.
Conclusions based on the magnitude of the
coefficient, as well as, the sign (+, or –)
associated with it were drawn using the
polynomial equation (Equation 1) resulting
from the analysis of data.
Y = 89.28 + 5.16X1 + 0.90X2 +
0.66X12 + 1.91X22 + 0.44X1X2

Bias (%) 

predictedvalue  observedvalue
x 100
predicted value

Eq. 2

Eq. 1
Physicochemical characterization
Particle size analysis and zeta potential

Statistically significant (p<0.05) values were
observed for the coefficients b0, b1, b2, b3, b4, and
b5. For this equation, the obtained correlation
coefficient (R2 = 0.9990) was found to be in
agreement with the predicted coefficient (R2 =
0.9884). Additionally, the estimated F value
(629.62) for the model were also found to be
significant (p<0.05). Finally, the positive sign
associated with coefficients (b1 and b2) indicated
a direct correlation between the studied
variables and the yield (%). These observations
supported the reliability of the developed
model for the study. Figure 1 shows the
response surface and contour plot reflecting the
influence of the studied variables on the yield
(%). The optimal values of the studied
variables, i.e. kaempferol: phospholipid ratio
(X1, w:w) and the reaction temperature (X2, °C)
were found to be 1:1, and 50°C for the
optimization of KPLC, respectively.

This Journal is © IPEC-Americas Inc

The particle size and zeta potential are
important physical characteristics of particulate
formulations such as KPLC. These parameters
are potentially indicative of the physical stability
and bioavailability of the formulation in
dispersion or suspension form. Nanoparticulate
systems, with lower average particle size, are
known to exhibit enhanced oral bioavailability.
Figure 2(A) shows the particle size distribution
of the optimized KPLC formulation. The mean
particle size of the prepared KPLC was found
to be 141.88 ± 1.23 nm. The polydispersity
index (PDI) of the formulation was found to be
0.33 ± 0.012. These findings are in agreement
with those reported previously for similar
formulations (13, 31).
Zeta potential (ζ), a measure of the surface
charge on the particles, is indicative of the
physical stability of the formulation in a
colloidal dispersion. Previously published
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Figure 1 The response surface plot and contour plots of entrapment efficiency (Y, %) as
a function of the ratio of kaempferol and Phospholipon® 90H (X1, w:w), and the reaction
temperature (X2, °C).

reports have suggested that the zeta potential
lower than 30 mV is related to particle
attraction followed by flocculation, exceeding
repulsion forces (14, 32, 33). Figure 2(B) shows
the distribution of zeta potential for the
prepared KPLC formulation. The zeta potential
for the prepared formulation was found to be This Journal is © IPEC-Americas Inc

18.70 ± 0.20. The zeta potential value depends
on the type and composition of phospholipids.
In KPLC, the low zeta potential value can be
attributed to the involvement of a portion of
phospholipids with generation of negative
charge in aqueous environment with relatively
neutral pH (34). Hence, smaller particle size,
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Figure 2 Particle size distribution (A) and zeta potential (B) of the optimized KPLC formulation.

lower polydispersity index and modest zeta
potential value for KPLC indicated an
acceptable physical stability and suitability for
oral administration.

thermograms. Information regarding drugexcipient interactions and formation of new
entities is often obtained from DSC analysis of
a formulation.

Differential Scanning Calometry (DSC)

Figure 3 shows the DSC thermogram obtained
from the analysis of pure kaempferol (A), pure
Phospholipon® 90H (B), PM (C), and KPLC
(D). As shown in Figure 3, pure kaempferol (A)
exhibited a sharp, endothermic, melting peak at
~285°C. The thermogram also showed a small,
broad peak at ~147°C. This peak can be
attributed to the loss of water molecules with
progressive increase in the temperature (35).
The thermogram of pure Phospholipon® 90H
(B) in Figure 3 showed two broad endothermic
peaks. The first, relatively larger peak at ~67°C,
and the second smaller peak at ~85°C. The
formation of first peak can be attributed to the
melting of the phospholipid molecule. The
second peak indicates a controlled phase

For pharmaceutically relevant materials, critical
information regarding their physical behaviors
such as melting, degradation, physical stability,
and compatibility of the formulation
components can be reliably obtained by
subjecting the samples to controlled
temperature changes. Differential scanning
calorimetry is among the well-established
techniques used for the thermal analysis of such
materials. Enthalpy changes, appearance/
disappearance of peaks, and changes to a
peak(s) onset time, shape, relative area, as a
function of temperature are exhibited in DSC

This Journal is © IPEC-Americas Inc
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Figure 3 DSC thermograms of (A) pure kaempferol, (B) Phospholipon® 90H, (C) the physical
mixture (1:1) of kaempferol and Phospholipon® 90H, and (D) KPLC.

transition, involving conversion from a gel-like
structure to a liquid crystalline structure; this
occurs through crystalline or isomeric changes
along the length of carbon chain of the
phospholipid molecule
(35-37). The
thermogram of the physical mixture (PM)
(Figureure 3C) also shows two dissimilar peaks,
a smaller endothermic peak at ~67ºC, and a
broader peak at ~103ºC. With formulation
components like the ones tested in this study,
controlled increase in temperature has been
reported to cause individual components to
form a partial complex in situ, which may melt
at temperatures lower than the individual
components (10). Finally, Figure 3D shows the
thermogram of the prepared KPLC. This
thermogram displayed a unique and a new
endothermic peak at ~80ºC, with the original
peaks of kaempferol or Phospholipon® 90H
being absent. These results are in agreement

This Journal is © IPEC-Americas Inc

with those reported earlier (38). These
observations, and the reports published
elsewhere, supports the formation of a stable
complex of kaempferol (KPLC). Weak
intermolecular forces such as hydrogen
bonding and van der Waals interactions
between the drug and the phospholipid
molecule are thought to be contributing to the
formation of such complexes (37, 39, 40). The
larger phospholipid molecule, with these
interactions, likely disperses kaempferol at a
molecular level by entrapping kaempferol
molecule.
Fourier
(FTIR)

Transform

Infrared

Spectroscopy

Figure 4 (A, B, C, and D) shows the FTIR
spectra of pure kaempferol, pure
Phospholipon® 90H, PM, and the optimized
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KPLC formulation. As shown in Figure 4A, the
spectra of pure kaempferol displayed
characteristic absorption peaks at ~3427 cm-1

and ~3317 cm-1 (phenolic O-H stretching),
~2954 cm-1 and ~2850 cm-1 (C-H stretching),
and at ~1613 cm-1 (C=O stretching). These

Figure 4 FTIR spectra of (A) pure kaempferol, (B) Phospholipon® 90H,
(C) the physical mixture (1:1) of kaempferol and Phospholipon® 90H,
and (D) KPLC.

This Journal is © IPEC-Americas Inc
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observations are consistent with those reported
earlier for kaempferol (41). Figure 4B shows
the FTIR spectrum of pure Phospholipon®
90H. The spectrum exhibited the characteristic
peaks at ~2918 cm-1 and ~2850 cm-1 (C-H
stretching in the fatty acid chain). Additional
signals observed were at ~1738 cm-1 (C=O
stretching in the fatty acid ester), ~1237 cm-1
(P=O stretching), ~1092 cm-1 (P–O–C
stretching), and at ~970 cm-1 [-N+ (CH2)3].
Similar results for phospholipid molecules have
been reported earlier (42-44). Figure 4C shows
the spectrum of the physical mixture (PM), and
reveals characteristic signals of the individual
components, i.e., kaempferol and
Phospholipon® 90H. The peaks were observed
at ~3304 cm-1, ~2918 cm-1, ~2850 cm-1, and
~1268 cm-1 (36). The FTIR spectrum of KPLC
is shown in Figure 4D, and exhibited peaks at
~3319 cm-1, ~2957 cm-1, ~2850 cm-1, ~2918
cm-1, ~1090 cm-1, and ~975 cm-1. When the
KPLC spectrum is compared with those of the
individual components, i.e. kaempferol, or
Phospholipon® 90H, it appeared that the
interaction of kaempferol with phospholipids
resulted in appearance of novel peaks,
disappearance of peaks specific to individual
components, as well as shifting of some peaks.
The kaempferol specific peaks at ~3317 cm-1
and ~2954 cm-1 were observed to be shifted to
~3319 cm-1 and ~2957 cm-1, respectively. Peaks
specific to Phospholipon® 90H were also found
to be significantly altered in the KPLC
spectrum. These observations support the
formation of KPLC as a result of weak
intermolecular interactions between kaempferol
and phospholipid molecules.
Proton Nuclear Magnetic Resonance (1H-NMR)

The 1H-NMR signal of pure kaempferol and
KPLC were recorded at 400 MHz frequency on
(δ) scale, and the spectra are shown in Figure 5
(A and B). The 1H-NMR spectrum signal of
pure kaempferol (Figure 5A) displayed
characteristic chemical shift values (δ, ppm; d6DMSO) below: 12.44 (s, 1H), 10.66 (s, 1H,),
10.04 (s, 1H) , 9.24, 8.04 (d, J = 12.0 Hz, 2H),
6.92 (dt, J = 8.8 Hz, 2.4 Hz, 2H), 6.40–6.17 (dd,

This Journal is © IPEC-Americas Inc

J = 8.8 Hz, 4 Hz, , 2H), 6.30 (d, J = 2.1 Hz,
1H), 6.09 (d, J = 2.1 Hz, 1H), The chemical
shift values (δ) obtained with these signals
showed good agreement with the previously
published literature (36, 41, 42, 45). The 1HNMR spectrum signal of Phospholipon® 90H
showed chemical shift values (δ, ppm) at 4.85
(1H, s), 4.08–3.96 (br s, 1H), 3.83–3.62 (s, 2H),
3.38 (s, 1H), 3.07 (s, 15H), 2.95 (d, J = 6.8 Hz,
8H), 2.27 (s, 1H), 1.26 (s, 2H, s), 0.95 (s, 23H),
0.57 (s, 3H, s) (41). The 1H-NMR of KPLC
(Figure 5B) displayed the following chemical
shift values (δ, ppm; d6-DMSO): 12.42 (s, 1H),
10.75 (s, 1H), 10.04 (s, 1H), 9.19 (s, 1H), 8.21,
8.05 (d, J = 9.0 Hz, 2H), 6.90 (d, J = 9.0 Hz,
2H), 6.39 (d, J = 2.1 Hz, 1H), 6.13 (d, J = 2.1
Hz, 1H), 3.18 (s, 2H), 1.24 (s, 6H). The shifts
observed at 1.24 ppm and 3.18 ppm in KPLC,
compared to free kaempferol and
Phospholipon® 90H relate to the alkyl side
chain and N-methyl group. By comparing the
chemical shifts among the three compounds, it
is clearly evident that weak intermolecular
bonding interactions exist between kaempferol
and Phospholipon® 90H, which renders the
formation of a stable KPLC.
Powder X-Ray Diffractometry (PXRD)

The Figure 6 (A, B, C, and D) shows the
diffractograms obtained from the powder x-ray
analysis of pure kaempferol, Phospholipon®
90H, PM, and KPLC, respectively. Multiple
sharp and intense peaks were observed in the
diffractogram of pure kaempferol at 2θ = 9°,
10°, 15°, 26°, and 27° (Figure 6A), in line with
its crystalline nature (12, 46). The diffractogram
of pure Phospholipon® 90H (Figure 6B)
displayed a single, relatively broad peak around
2θ = 21º. The amorphous nature of
phospholipid molecule was evident by the
absence of any sharp crystalline peak. These
observations are in agreement with those
reported earlier (47, 48). Figure 6C displays the
x-ray diffractogram of a physical mixture of
kaempferol and Phospholipon® 90H. The
diffraction pattern of the physical mixture
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Figure 5 1H-NMR spectra of (A) kaempferol, and (B) KPLC.

exhibited a few low-intensity crystalline peaks
and a relatively broader peak likely associated
with kaempferol and Phospholipon® 90H,
respectively. Lower amount of kaempferol
compared to phospholipid in the mixture,
interference by the phospholipid molecule, or in
situ partial formation of a complex between
This Journal is © IPEC-Americas Inc

kaempferol and phospholipids could have
possibly caused the observed decrease in the
intensity of crystalline peaks. Partial
amorphization of kaempferol due to its close
association with phospholipid also cannot be
ruled out. Finally, as shown in Figure 6D, the
diffractogram of KPLC revealed two, broad, ill-
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Figure 6 The x-ray diffractograms of (A) pure
kaempferol, (B) Phospholipon® 90H, (C) the
physical mixture (1:1) of kaempferol and
Phospholipon® 90H, and (D) KPLC.

defined, and closely situated peaks at 2θ = 20°
and 2θ = 26°. The peak at 2θ = 20° could be
associated with the Phospholipon® 90H,
This Journal is © IPEC-Americas Inc

whereas the peak observed at 2θ = 26° could be
thought of as a remnant signature of
kaempferol. Other peaks defining the crystals
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of kaempferol were absent. These observations
indicate that kaempferol may be molecularly
dispersed in a matrix of phospholipid, and a
major fraction is present in an amorphized
form (49).
Solubility analysis

Table 3 shows the results from solubility
analysis of pure kaempferol, PM, and KPLC as
measured in water and n-octanol. The aqueous
solubility of pure kaempferol was found to be
~1.25 µg/ml; whereas, its solubility in noctanol was observed to be ~902.73 µg/ml.
These observations indicated that kaempferol
molecule is predominantly lipophilic in nature
and belongs to Class II (low solubility/high
permeability) of the Biopharmaceutics
Classification System (BCS). The analysis of the
physical mixture (PM) revealed that kaempferol
solubility in n-octanol remained practically
unchanged (~904.68 µg/ml), while its aqueous
solubility was found to increase significantly
(p<0.01) compared to pure kaempferol. Over 6fold increase (~8.23 µg/ml) in the aqueous
solubility of kaempferol was observed in the
physical mixture. This observed increase in
kaempferol aqueous solubility can be attributed
to the presence of amphiphilic phospholipid
molecules in close proximity to kaempferol
molecules. The aqueous solubility of
kaempferol in the prepared KPLC exhibited a
dramatic and significant (p<0.001) increase
(~35.68 µg/ml),

compared to either pure kaempferol or PM.
Over 28-fold increase in aqueous solubility of
kaempferol was observed with KPLC
compared to that of pure kaempferol. A
modest increase (~908.98 µg/ml) in the
solubility of kaempferol in n-octanol was also
observed with KPLC. The dispersion of
kaempferol molecules within the amphiphilic
phospholipid molecules, resulting in partial
amorphization of kaempferol may be attributed
to this observed increase in aqueous solubility
of kaempferol in the prepared KPLC (36, 37).
Functional characterization
In vitro dissolution studies

The results of the comparison of dissolution
profiles of pure kaempferol with that of the
prepared KPLC in phosphate buffer (pH 7.4)
are shown in Figure 7. These results show that
for the first 5 hours the release profiles of
kaempferol and KPLC almost overlapped and
there was no significant difference between the
profiles. The dissolution of pure kaempferol
appeared to reach a plateau, and exhibited
maximum dissolution of ~31% at the end of 12
hours. The release of kaempferol from KPLC,
however, continued to steadily increase
reaching over 70% by the end of 12 hours.

Table 3 Solubility analysis of pure kaempferol, the physical mixture (1:1) of kaempferol and Phospholipon® 90H (PM),
kaempferol-Phospholipon® 90H complex (KPLC).

SAMPLE

AQUEOUS SOLUBILITY (μg/ml)*

n-OCTANOL SOLUBILITY (μg/ml)*

Kaempferol

1.25 ± 0.33

902.73 ± 0.29

PM

8.23 ± 0.78

904.68 ± 0.60

KPLC

35.68 ± 1.15

918.98 ± 1.08

*Data expressed as mean ± Std. Dev. (n = 3)

This Journal is © IPEC-Americas Inc
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Figure 7 The in vitro dissolution profiles of kaempferol release from kaempferol suspension,
and KPLC. Values are mean ± Std. Dev. (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001
(significant with respect to pure kaempferol).

The observed increase in the kaempferol
dissolution from KPLC may be attributed to its
increased aqueous solubility in the complex.
Moreover, increased wettability of the complex
may also have contributed to the observed
increase in the rate and extent of dissolution
(50).
Various kinetic models viz., zero order, first
order, Higuchi, and Korsmeyer-Peppas model
were explored to determine the model-fit of the
release profile of KPLC (data not shown).
Based on the obtained value of the regression
This Journal is © IPEC-Americas Inc

coefficient (R2=0.9783), the Higuchi model was
found to be the best representative model
describing the dissolution of KPLC.
Additionally, the release exponent value (n) was
estimated to be 0.47, thus indicating a nonFickian release. The release mechanism of
kaempferol, as determined by the KorsmeyerPeppas model, was a two-step diffusion. The
dissociation of kaempferol molecules from the
KPLC matrix was followed by the diffusion of
kaempferol molecules out the phospholipid
matrix (51). Thus, KPLC was found to
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significantly enhance both the rate and the
extent of kaempferol release compared to pure
kaempferol.
In Vivo antioxidant activity
Liver function test

Table 4 shows the results of influence of pure
kaempferol and KPLC on the markers of CCl4induced hepatic damage in rats. CCl4 is known
to be bio-transformed by the liver CYP450
enzymes to produce free radicals. These free
radicals covalently bind to cellular
macromolecules (e.g. lipids, nucleic acids,
proteins, etc.) and result in oxidative damage to
several vital organs such as heart, kidney, brain,
and liver (52). The rats treated with CCl4 alone
showed a significant increase in the marker
enzymes viz., SGOT, SGPT, SALP, and total
bilirubin. A significant (p<0.05) prevention of
this increase was observed in rat treated with
pure kaempferol (25 mg/kg, p.o.) for 7
consecutive days.

Additionally, the rats treated with KPLC
(~25mg/kg kaempferol, p.o.) for 7 consecutive
days also showed a significantly (p<0.01)
improved hepatoprotective activity by
preventing the increase in the levels of these
markers after CCl4 administration.
In vivo antioxidant marker enzyme estimation

Several studies have reported the reliability of
the levels of hepatic enzymes GSH, SOD,
CAT, and LPO as indicators of in vivo
antioxidant activity (17, 18, 29, 52, 53).
Kaempferol is reported to have excellent
antioxidant and hepatoprotective properties (2,
3). The results of the influence of pure
kaempferol and KPLC on the levels of GSH,
SOD, CAT, and LPO in CCl4-treated and naïve
mice are shown in Figure 8. Animals treated
with CCl4 alone showed a significant (p<0.05)
reduction in the levels of GSH compared to
animals receiving vehicle.

Table 4 Effect of pure kaempferol and KPLC on CCl4-intoxicated rat hepatic marker enzymes, Serum GlutamicPyruvate Transaminase (SGPT), Serum Glutamic – Oxaloacetate Transaminase (SGOT), Alkaline Phosphatase (ALP),
and total bilirubin.

ANIMAL TREATMENT
GROUPS

SGPT
(IU/L)a

SGOT
(IU/L)a

SALP
(IU/L)a

TOTAL BILIRUBIN
(mg/dL)

23.05 ± 1.58**

24.30 ±1.54**

142.60 ± 2.20**

0.37 ± 0.03**

40.16 ±2.74

49.21 ± 2.91

179.30 ± 4.14

0.79 ± 0.05

(Group III)
Kaempferol (25 mg/kg, p.o.)
+ [CCl4 + olive oil
(1:1, 5 mL/kg, i.p., day 7)]

33.28 ± 1.27*

42.10 ± 2.31*

166.15 ± 2.72*

0.55 ± 0.03*

(Group IV)
KPLC (~25 mg/kg, p.o.)
[CCl4 + olive oil
(1:1, 5 mL/kg, i.p., day 7)]

25.19 ± 1.11**

28.35 ± 2.12**

149.20 ± 2.05**

0.42 ± 0.02**

(Group I) Normal
Tween® 20 (1%, v/v, p.o.)
(Group II)
Control: CCl4 + olive oil
(1:1, 5 mL/kg, i.p.)

a
- IU/L = International Units/Liter of Plasma,
All values are expressed as Mean ± Std. Error of Mean (n = 6)
*p<0.05, **p<0.01 (Significant with respect to control group)
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Figure 8 Influence of pure kaempferol and KPLC on rat liver antioxidant marker enzymes, i.e.
glutathione reductase (GSH) (nmoles/mg of protein), superoxide dismutase (SOD) (units/mg
protein), catalase (CAT) (units/mg protein), and lipid peroxidation (LPO) (nmoles of MDA
released /g tissue). Values are Mean ± Std. Error of Mean (n = 6). *p < 0.05, **p < 0.01
(significant with respect to control: CCl4-only treated groups).

The animal group receiving pure kaempferol
exhibited a significant (p<0.05) prevention
against CCl4-induced reduction in GSH levels.
The CCl4-induced lowering of GSH levels in
the liver homogenate was also prevented, albeit
with a higher significance (p< 0.01) after
treatment with KPLC (~25 mg/kg kaempferol,
p.o.). The treatment with CCl4 revealed a
This Journal is © IPEC-Americas Inc

significant (p<0.01) reduction in the SOD levels
in rat liver homogenate. The animal group
treated with pure kaempferol (25 mg/kg, p.o.)
resulted in a significant (p<0.05) prevention of
CCl4-induced reduction in SOD levels.
Treatment with KPLC (~25 mg/kg
kaempferol, p.o.) further prevented CCl4induced lowering of SOD significantly

December 2016

J. Excipients and Food Chem. 7 (4) 2016 -

109

Original Article
(p<0.01). The levels of the enzyme CAT were
observed to decrease significantly (p<0.01) after
treatment with CCl4, compared to animals
receiving vehicle alone. Oral treatment with
pure kaempferol (25 mg/kg, p.o.) significantly
(p< 0.05) prevented this CCl4-induced
reduction in CAT levels. Kaempferol was
found to be more effective, and highly
significant (p<0.01) in preventing CCl4-induced
reduction in CAT levels when administered in
the form of KPLC. Lipid peroxidation,
measured as MDA (nM/g) in hemoglobin was
found to increase significantly (p<0.01) after
CCl4 treatment. The administration of pure
kaempferol (25 mg/kg, p.o.) prevented CCl4induced lipid peroxidation significantly
(p<0.05). The animal group treated with KPLC
(~25 mg/kg apigenin, p.o.) also showed a
prevention of CCl4-induced increase in lipid
peroxidation, albeit with a higher significance
(p< 0.01).
Histopathological studies

The influence of pure kaempferol, or KPLC
treatment on the CCl4-induced hepatic damage
was assessed by investigating the
histopathology of rat liver tissues. The
hematoxylin-eosin stained microscopic (400×)
images of liver tissues after treatment with
Tween® 20, CCl4, pure kaempferol + CCl4, or
KPLC+ CCl4 are shown in the Figure 9A, 9B,
9C, and 9D, respectively. The animals treated
with vehicle, i.e. Tween® 20 (1%, v/v) showed
well-preserved hepatic cellular organelles
indicating healthy, well-functioning liver
physiology (Figure 9A). Treatment with CCl4
appeared to result in a significant and a visible
degeneration of parenchymal cells and fatty
tissues, and a significant damage to the central
lobular vein (Figure 9B). Pure kaempferol
treatment (25 mg/kg, p.o.) exhibited a degree
of hepatoprotective activity against CCl4induced hepatic damage (Figure 9C). The
animals receiving KPLC (~25 mg/kg
kaempferol, p.o.) demonstrated a significant
protection against CCl4-induced hepatic
This Journal is © IPEC-Americas Inc

degeneration (Figure 9D). Thus, the antioxidant
properties of kaempferol, both in pure form
and in KPLC were evident by the restoration of
normal anatomy of the hepatic cellular
structures after these treatments.
Oral bioavailability studies

The oral bioavailability of pure kaempferol and
KPLC was determined by analyzing the rat
plasma samples via HPLC method. The peak
resolution, signal-to-noise ratio, and the
duration of sample analysis were improved by
optimizing the chromatographic conditions. In
this study, we used quercetin as internal
standard, due to its structural similarity with
pure kaempferol. In order to produce optimal
sensitivity and peak resolution efficiency
between kaempferol and quercetin, various
solvent/buffer systems were evaluated.
Acetonitrile was found to be an optimal mobile
phase for resolving kaempferol and quercetin
peaks, with an acceptable run time of 6.0
minutes. It was also observed that the addition
of phosphoric acid (0.4%) to acetonitrile
significantly improved the peak shape and
resolution efficiency. The wavelength of 360
nm was chosen for the detection of both
components.
In addition to the HPLC method optimization,
it was important to identify an optimal
technique for the extraction of kaempferol
from plasma. Commonly employed techniques
for drug extraction from plasma include solidliquid extraction, liquid-liquid extraction, and
protein precipitation. Solid-liquid extraction is
known to exhibit excellent recovery and
reproducibility. The technique, however, is
reported to be complex and expensive, and
limited to the rapid processing of multiple
samples (54). Due to multiple extracting steps
involved, the protein precipitation technique is
cost-prohibitive, and the sample recovery also
reported as being rather low (55, 56). Thus, for
the current study, the plasma samples were
processed using liquid-liquid extraction via
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Figure 9 Histopathology micrographs (×400) of rat livers. (A) Normal: Tween® 20 (1%, v/v, p.o.), (B)
Control: CCL4 + olive oil (1:1, 5 mL/kg, i.p.), (C) Pure kaempferol (25 mg/kg, p.o.) + [CCL4 + olive oil (1:1,
5 mL/kg, i.p., day 7)], and (D) KPLC (~25 mg/kg kaempferol, p.o.) + [CCL4 + olive oil (1:1, 5 mL/kg, i.p.,
day 7)].

hydrolysis with hydrochloric acid (0.2 M). With
this technique a high recovery was observed , as
well as, accuracy in detecting kaempferol and
quercetin.
Figure 10 shows the mean plasma
concentration-time profiles of kaempferol in
the plasma of animals treated with pure
kaempferol (100 mg/kg, p.o.) or KPLC (~100
mg/kg, p.o.). The group treated with KPLC
exhibited a significantly higher plasma
This Journal is © IPEC-Americas Inc

concentration of kaempferol compared to the
group treated with pure kaempferol, between
30 minutes and 8 hours. The concentrationtime profile of pure kaempferol showed a nearplateau form with the levels of kaempferol
never exceeding 0.2 μg/ml during the analysis
period. The pharmacokinetic profile of KPLC
exhibited an immediate increase in plasma
kaempferol concentration, which peaked to
~1.5 μg/ml at 30 minutes. This was followed
by a steady decrease in plasma kaempferol
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Figure 10 Mean plasma concentration-time profile after oral administration of pure kaempferol (100 mg/kg, p.o.) or
KPLC (~100 mg/kg kaempferol, p.o.). Values are mean ± Std. Dev. (n = 6). *p < 0.05; **p < 0.01, and ***p < 0.001
(significant with respect to pure kaempferol treated group).

concentration for a period of 8 hours.
Table 5 lists the pharmacokinetic parameters
calculated from the plasma concentration-time
profiles, using a statistical software
(WinNonlin®, Version 4.1, Certara USA Inc.,
Princeton, NJ, USA). The calculated values of
bioavailability-indicating pharmacokinetic
parameters such as Cmax, Tmax, and AUC0-4 were
found to be significantly higher in the treatment
group receiving KPLC, compared to that
receiving pure kaempferol. Additionally, this
group also exhibited significantly lower values
for elimination half-life (t½ el), clearance (cl/F),
and volume of distribution (Vz/F). The
elimination rate constant (Kel) however, was
found to be higher in the group treated with
KPLC compared to that treated with pure
This Journal is © IPEC-Americas Inc

kaempferol. Additionally, the calculated
bioavailability (F) of kaempferol after KPLC
administration was observed to be ~100%.
These observations led us to infer that KPLC
treatment resulted in higher bioavailability and
prolonged in vivo presence of kaempferol.
Complexation with phospholipid molecules,
resulting in increased aqueous solubility and
gastrointestinal absorption, is likely responsible
for the enhanced relative bioavailability of
kaempferol observed after a single oral
administration of KPLC. While phospholipidbased complexation has exhibited enhanced
bioavailability of kaempferol, factors such as
dietary lipid intake and other internal or
external factors may significantly affect the rate
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Table 5 Pharmacokinetic parameters, for group of animals after oral administration of pure kaempferol (25 mg/kg, p.o.)
and KPLC (~25 mg/kg, p.o.)
TREATMENT
PHARMACOKINETIC PARAMETERS

PURE KAEMPFEROL
(100 mg/kg, p.o.)*

KPLC
(~100 mg/kg of kaempferol, p.o.)*

Cmax (µg ml-1)

0.18 ± 0.12

1.48 ± 0.41

Tmax (hours)

1.0 ± 0.51

0.5 ± 0.37

Area under concentration –time curve (AUC0 – t)
( (µg ml-1 h)

0.67 ± 0.21

3.72 ± 0.58

Area under concentration –time curve (AUC0 – 4)
( (µg ml-1 h)

0.89 ± 0.41

3.74 ± 0.73

Elimination half-life(t1/2el) (h)

3.85 ± 0.16

1.20 ± 0.24

-1

Elimination rate constant (Kel) (h )

0.17 ± 0.04

0.57 ± 0.02

Clearance (cl/F) [(mg)/(µgml-1h-1)]

112.32 ± 1.69

26.69 ± 0.83

Volume of distribution (Vz/F) [(mg)/(µgml-1h-1)]

624.39 ± 0.57

46.47 ± 0.42

*Values are expressed as mean ± Std. Error of Mean (n = 6)

and extent of drug absorption from such
systems. It is important to consider the use of
suitable biorelevant media, and other
experimental conditions when evaluating the
solubility and permeability of drugs via such
systems (57).
CONCLUSIONS

Improved aqueous solubility and oral
bioavailability, resulting in excellent in vivo
antioxidant activity of kaempferol with
phospholipid-based complex, were the main
outcomes of the present work. The study
presented a simple, yet robust, method to
prepare a KPLC formulation, optimized using a
full-factorial design. Characterization by DSC,
FTIR, 1H-NMR, and PXRD supported the
formation of a stable complex via non-covalent
bonding interactions such as hydrogen
bonding, ion-dipole, and van der Waals
interactions. The increased aqueous solubility
of the prepared KPLC as compared to PM or
pure kaempferol was demonstrated by solubility
analysis. Functional characterization revealed
the enhanced dissolution of KPLC compared
to pure kaempferol. The in vivo antioxidant
activity of KPLC was also shown to be
relatively higher compared to that of pure

This Journal is © IPEC-Americas Inc

kaempferol, in a small rodent hepatotoxicity
model. The analysis of pharmacokinetic
parameters revealed an enhanced oral
bioavailability of kaempferol from the prepared
complex. The value of using phospholipids to
improve the solubility, oral bioavailability and
pharmacological properties, is further validated
by this study.
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